Catalyst Event

Daewoong Pharmaceutical Co Ltd (069620) · Other

From KRX Bio Technology Transfer Index (KBIOTT)

5/21/2026, 12:00:00 AM

OtherSentiment: Positive

Daewoong Pharmaceutical announced a license-in agreement for a long-acting obesity treatment on 2026-05-21. This entry into the high-growth obesity market is estimated to cause a ≥10% price impact. scheduled

Korean Translation

2026-05-21 비만치료용 장기지속형 주사제 기술도입 계약을 체결함. 고성장 비만 치료제 시장 진출로 10% 이상의 주가 영향이 예상됨. 예정됨

Related Recent Events

View Full Timeline